Hematologic Malignancy Clinical Trial
— VIRTUOSOOfficial title:
Using of Virtual Reality to Relieve Procedural Pain in Pediatric Oncology.
Medical procedures can be a very frightening experience for children. It is known that children who received painful medical procedures can develop a higher sensitivity of pain during their following experiences. During their treatments for malignant diseases, children are exposed to a lot of painful procedures (eg. needle insertion, lumbar punction, myelogram, etc…) Therefore, medical societies propose the use of interventions like distraction techniques for pain management in complement of pharmacological treatment. In addition, the repetitions of painful procedures and ineffective prevention of pain can create care phobia. Within this context, immersive and participative virtual reality (VR) could be an innovative distraction technique for pain management among children undergoing medical procedures. Attention Pain Theory can explain how virtual reality can reduce the perception of pain. Attention is required to feel pain. When the patient is focused on another subject like an immersive virtual environment, his brain is less available to treat information like painful stimulus from care procedures. The investigators hypothesis is that VR can reduce procedural-related pain and can decrease fear during the following procedures. Results of previous studies are varied : some showed a non-significant reduction of patient's procedural pain despite the use of VR, whereas others concluded to a decrease of pain. The question of the benefit of VR for the patients who are exposed to repeated painful procedures remains still unclear, especially with patients who are likely to feel chronic pain or many pain-related exposures. The aim of this study is to evaluate the non-inferiority of virtual reality as a distraction technique for pain management in children and adolescents with onco-hematological diseases, undergoing painful procedures, compared to standard of care.
Status | Recruiting |
Enrollment | 34 |
Est. completion date | February 11, 2025 |
Est. primary completion date | February 11, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 7 Years to 18 Years |
Eligibility | Inclusion Criteria: Quantitative component: - Child aged 7 to 18 years - Child followed in pediatric onco-hematology in the context of hematological malignancy or non malignant hematology or solid tumor management. - Child who has already experienced a potentially painful care procedure before entry the study - Child who will have the same potentially painful care procedure (Hüber needle placement or lumbar puncture) on three occasions during the course of their care. - Child with consent. - Child whose parental authority holders have given their consent to participate to the study. Qualitative component: - Professional who used both care-induced pain prevention techniques and agreed to be interviewed. - A parent or guardian. Exclusion Criteria: - Child who refuse to use this distraction technique (VR). - Child who refuse to not use MEOPA during VR. - Child who hasn't experienced the potentially painful care procedure that will be done during the study at least once before inclusion - Child who does not speak French and whose parents do not speak French |
Country | Name | City | State |
---|---|---|---|
France | Nantes CHU | Nantes |
Lead Sponsor | Collaborator |
---|---|
Nantes University Hospital | For Ever Fabien |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pain level measured by VAS (self-evaluation) during the first care using standard treatment. | Pain levels measured on the VAS. VAS : Visual Analogue Scale . Minimum value : 0. Maximum value : 10. The maximum value is the worse outcome. | Immediately after the first care. | |
Primary | Pain level measured by VAS (self-evaluation) during the second care using virtual reality | Pain levels measured on the VAS. VAS : Visual Analogue Scale . Minimum value : 0. Maximum value : 10. The maximum value is the worse outcome. | Immediately after the second care . | |
Primary | Pain level measured by VAS (self-evaluation) during the third care using virtual reality or standard treatment | Pain levels measured on the VAS. VAS : Visual Analogue Scale . Minimum value : 0. Maximum value : 10. The maximum value is the worse outcome. | Immediately after the third care . | |
Secondary | Percentage of children who choose VR in the 3rd care | Patient preference between VR and usual pain prevention technique for the same care.
The difference between the pain level measured on a VAS with the use of VR and the pain level with the usual technique. VAS : Visual Analogue Scale . Minimum value : 0. Maximum value : 10. The maximum value is the worse outcome. |
Immediately after the 3rd intervention. | |
Secondary | Patient questionnaire | Analysis of the answers to the patient questionnaire after treatment n°3. Description of the reasons for selecting the preferred technique. | Immediately after the 3rd intervention. | |
Secondary | Side effects to the use of VR | Record of side effects reported in the e-CRF. Description of the potential side effects to the use of VR in care. | During each intervention with virtual reality (care 2 and care 3 if VR is chosen). Up to 6 months. | |
Secondary | Ethnographic approach to caregivers' experiences after using the VR headset. | Direct observation of the care unit. Understand the obstacles and levers for professionals to implement a new pain prevention device during care. | Through study completion - up to 20 months. | |
Secondary | parent questionnaire. | Analysis of the responses to the parent questionnaire. Understand parents' experience of care when implementing a new pain prevention device during care. | Immediately after the 3rd intervention. | |
Secondary | Thematic analysis of the verbatim collected during the semi-directive interviews with the parents after Care 3 | Understand the social representations of parents and children regarding the use of a virtual reality device. | Immediately after the 3rd intervention. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04889937 -
Usability, Adherence and Diagnostic Performance of PointCheck in Pediatric Population
|
||
Not yet recruiting |
NCT05820126 -
Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial
|
Phase 2 | |
Active, not recruiting |
NCT04509765 -
A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT
|
N/A | |
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Withdrawn |
NCT03986086 -
MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT02512666 -
Non Invasive Optical Imaging of WBC Count
|
N/A | |
Withdrawn |
NCT02207764 -
Reiki as a Complementary Therapy: A Pilot Study
|
N/A | |
Not yet recruiting |
NCT02193399 -
Physiotherapy in Hematopoietic Stem Cell Transplantation
|
N/A | |
Terminated |
NCT01846429 -
Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain
|
Phase 1 | |
Terminated |
NCT01215981 -
Influenza Vaccine Post Allogeneic Transplant
|
N/A | |
Completed |
NCT00333190 -
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
|
N/A | |
Withdrawn |
NCT04392128 -
Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)
|
Phase 2 | |
Recruiting |
NCT06102213 -
Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation
|
Phase 2 | |
Active, not recruiting |
NCT04552288 -
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
|
Phase 2 | |
Completed |
NCT03654404 -
A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients
|
N/A | |
Recruiting |
NCT05384288 -
Response to Influenza Vaccination in Pediatric Oncology Patients
|
||
Recruiting |
NCT05084027 -
Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT
|
Phase 2 |